Angiomax Generic From Hospira Might Launch At-Risk Launch In 2015
This article was originally published in The Pink Sheet Daily
District Court upholds validity of TMC’s process patents for its anticoagulant but finds Hospira does not infringe them.
You may also be interested in...
Exactly when The Medicine Co.'s top seller will see competition isn't clear – highlighting industry concerns with FDA review times for ANDAs. Hospira and Sagent have tentative approval and several other firms have pending applications.
CEO Clive Meanwell detailed plans to deploy a 400-person commercial group in the U.S. to target 1,100 leading hospitals in the U.S.
While readying an appeal to a patent ruling benefiting Hospira’s efforts to introduce an Angiomax generic, the hospital-care specialist has several drugs nearing regulatory decisions in the U.S. and Europe.